Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure

European Journal of Heart Failure

Volumn 9, Issue 2, 2007, Pages 202-208

  Berger, Rudolf ^a,b   Moertl, Deddo ^a,b   Huelsmann, Martin ^a,b   Bojic, Anja ^a,b   Ahmadi, Roozbeh ^a,b   Heissenberger, Isabella ^a,b   Pacher, Richard ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Ludwig Boltzmann Institut HTA   (Austria)

Author keywords

Beta blocker; Heart failure; Positive inotropes; Vasodilators

Indexed keywords

ALPROSTAPINT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; LEVOSIMENDAN; PROSTAGLANDIN E1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTHRALGIA; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CHOLECYSTITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEART ASSIST DEVICE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; HYPOTENSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ALPROSTADIL; CARDIOTONIC AGENTS; DRUG INTERACTIONS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; PYRIDAZINES; STROKE VOLUME; VASODILATOR AGENTS;

EID: 33847787867     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2006.06.001     Document Type: Article

References (30)

1. Braunwald E. Expanding indications for beta-blockers in heart failure. N Engl J Med 344 (2001) 1711-1712
2. Packer M., Coats A.J.S., Fowler M.B., et al., for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
3. Bristow M.R., Gilbert E.M., Abraham W.T., et al., for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94 (1996) 2807-2816
4. Rouleau J.L., Roecker E.B., Tendera M., et al. Influence of pre-treatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure. J Am Coll Cardiol 43 (2004) 1423-1429
5. Cleland J.G., Freemantle N., Coletta A.P., and Clark A.L. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 8 (2006) 105-110
6. Haikala H., Kaivola J., Nissinen E., Wall P., Levijoki J., and Linden I.B. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 27 (1995) 1859-1866
7. + channel in rat ventricular cells. J Pharmacol Exp Ther 283 (1997) 375-383
8. Follath F., Cleland J.G., Just H., et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360 (2002) 196-202
9. Kivikko M., Antila S., Eha J., Lehtonen L., and Pentikainen P.J. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol 42 (2002) 43-51
10. Kersten J.R., Montgomery M.W., Pagel P.S., and Warltier D.C. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 90 (2000) 5-11
11. Stanek B., Sturm B., Frey B., et al. Bridging to heart transplantation: prostaglandin E1 versus prostacyclin versus dobutamine. J Heart Lung Transplant 18 (1999) 358-366
12. Stanek B., and Pacher R. Intravenous therapy for advanced heart failure. Curr Opin Cardiol 15 (2000) 156-160
13. Frey B., Pacher R., Locker G., et al. PGE1 improves hemodynamics and neurohumoral activity in potential HTx candidates on long term. Chest 117 (2000) 1713-1719
14. Mehrabi M.R., Serbecic N., Tamaddon F., et al. Revascularization of myocardial scar tissue following prostaglandin E1-therapy in patients with ischemic heart disease. Pathol Res Pract 199 (2003) 129-136
15. Berger R., Huelsman M., Strecker K., et al. Prognostic power of neurohormones depends on the mode of death in patients with chronic heart failure-neurohormonal risk stratification of sudden death and pump failure. Eur J Clin Invest 35 (2005) 24-31
16. Harrison A., Morrison L.K., Krishnaswamy P., et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 39 (2002) 131-138
17. Davidov M.E., Sing S.P., Vlachakis N.D., et al. Bisoprolol, a once-a-day beta-blocking agent for patients with mild to moderate hypertension. Clin Cardiol 17 (1994) 263-268
18. 1-adrenoceptor selectivity of bisoprolol. Eur J Clin Pharmacol 40 (1991) 135-139
19. Hall S.A., Cigarroa C.G., Maroux L., et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 25 (1995) 1154-1161
20. Shakar S.F., Abraham W.T., Gilbert E.M., et al. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol (1998) 1336-1340
21. Packer M., Carver J.R., Rodeheffer J.R., et al., for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325 (1991) 1468-1475
22. Fonarow G.C. The treatment targets in acute decompensated heart failure. Rev Cardiovasc Med 2 Suppl 2 (2001) S7-S12
23. Murali S., Uretsky B.F., Armitage J.M., et al. Utility of prostaglandin E1 in the pretransplantation evaluation of heart failure patients with significant pulmonary hypertension. J Heart Lung Transplant 11 (1992) 716-723
24. Elkayam U. Tolerance to organic nitrates: evidence, mechanisms, clinical relevance, and strategies for prevention. Ann Intern Med 114 (1991) 667-677
25. Friederich J.A., and Butterworth J.F.t. Sodium nitroprusside: twenty years and counting. Anesth Analg 81 (1995) 152-162
26. Vrtovec B., Delgado R., Zewail A., et al. Prolonged QTc interval and high B-type natriuretic peptide levels together predict mortality in patients with advanced heart failure. Circulation 107 (2003) 1764-1769
27. Moertl D., Berger R., Huelsmann M., Bojic A., and Pacher R. Short term effects on hemodynamic parameters and B-type natriuretic peptide levels of levosimendan compared to prostaglandin E1 in patients withchronic decompensated heart failure. Eur J Heart Fail 7 (2005) 1156-1163
28. Davis M.E., Richards M., Nicholls G., Yandle T.G., Frampton C.M., and Troughton RW. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 113 (2006) 977-985
29. Anand I.S., Fisher L.D., Chiang Y.T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003) 1278-1283
30. Spargias K.S., Anifantakis A., Papadakis M., et al. Preliminary clinical experience with the repetitive administration of levosimendan in patients with end-stage heart failure. Ital Heart J 4 (2003) 45S-49S